摘要
目的观察瑞波西汀合并氯氮平治疗精神分裂症阴性症状的疗效和不良反应。方法筛选出114例慢性精神分裂症患者,采用随机双盲法,将其分为研究组(瑞波西汀+氯氮平)(n=57)和对照组(安慰剂+氯氮平)(n=57),实验期间,氯氮平剂量不变,瑞波西汀为8mg(装入空胶囊两粒)/日,安慰剂与瑞波西汀等量(淀粉胶囊两粒)/日。在治疗前及治疗后4、8、12周末分别以阳性和阴性症状量表总分、阴性因子分评定疗效和不良反应量表评定不良反应。结果治疗12周末,研究组PANSS总分、阴性因子分及一般精神病理分均低于治疗前(P<0.05或P<0.01),与对照组比较,差异有统计学意义(P<0.05或P<0.01);阴性因子中除交流缺乏自发性和流畅性外各项症状评分均低于对照组(P<0.05或P<0.01)。结论瑞波西汀合并氯氮平治疗精神分裂症阴性症状安全有效。
Objective To observe the efficacy and side effects of reboxetine combined with clozapine in treating negative symptoms of schizophrenia. Methods In the random study, 114 inpatients with chronic schizophrenia who recruited for this study were divided into research group taking reboxetine combined clozapine（n=57） and control group taking placebo combined clozapine（n=57）. The subjects in the research group received 8mg of reboxetine/day that was loaded space capsules（2 capsules） while clozapine was continued, and the others received the same doses（2 starch capsules）. Efficacy and side effects were assessed with positive and negative syndrome scale and treatment emergent symptoms scale respectively before and after 4,8,12 week treatment. Results After 12-week treatment, the total scores of PANSS, negative scores, general psychopathology scores in research group were significantly different than that before treatment（P〈0.05 or P〈0.01）. There was statistic significance（P〈0.05 or P〈0.01） except lack of spontaneity and flow of conversation, so did every factor score of negative scores（P〈0.05 or P〈0.01）. Conclusion It is suggested reboxetine in combination with clozapine is effective and safe in treatment of the negative symptom in schizophrenia patients.
出处
《中国现代医生》
2008年第1期13-15,共3页
China Modern Doctor
